Table 3 Percentages of adolescents and "elderly" persons with risk alleles

Biotransformation Phase I

CYP1A2

-154C

32.3

36.8

7.3

7.0

0,468

0,509

CYP1A1

3801C

15.1

21.1

2.3

3.3

0,197

0,276

CYP1A1

462V

6.9

6.3%

0.0

0.0

0,069

0,063

CYP1A1

461N

7.6

7.8

0.5

0.0

0,085

0,078

CYP2E1

-70T

6.0

8.8

0.0

0.5

0,060

0,098

CYP3A4

-391G

6.0

5.8

1.1

0.5

0,083

0,068

Biotransformation Phase II

GSTM1

Del

n.a.¹

n.a.¹

56.6

53.4

1,136

1,068

GSTT1

Del

n.a.¹

n.a.¹

18.4

14.3

0,367

0,286

GSTP1

105V

52.3

47.4

16.8

10.5

0,859

0,684

GSTP1

114V

12.5

14.5

2.5

1.0

0,175

0,165

NAT2

114T

49.9

49.6

30.6

19.8

1,113

0,892

NAT2

197Q

39.9

42.9

8.8

6.5

0,576

0,559

NAT2

286E

3.9

5.5

0.0

0.3

0,039

0,060

DNA Repair

BRCA2

A-26

29.9

38.2

3.7

6.1

0,375

0,504

BRCA2

372H

46.2

41.5

9.4

10.6

0,657

0,628

XRCC1

R194

11.0

12.7

0.5

0.8

0,120

0,142

XRCC1

280H

9.7

9.4

0.5

0.3

0,108

0,099

XRCC3

241M

49.8

44.1

16.4

19.5

0,829

0,830

XPD

751Q

42.8

49.9

14.5

11.1

0,720

0,722

XPD

156R

43.7

51.9

24.6

19.7

0,933

0,914

APE1

148G

48.3

47.5

25.2

27.9

0,989

1,033

OGG1

326C

37.2

35.9

7.1

6.6

0,517

0,491

Oxidative Stresss

mnSOD

16A

51.7

51.3

22.4

24.1

0,968

0,995

CAT

-262T

30.0

31.7

9.8

8.8

0,499

0,494

NQO1

187S

13.3

5.3

0.2

0.3

0,140

0,058

NQO1

139W

31.1

31.4

4.6

4.3

0,405

0,399

MPO

G-463

32.0

36.8

4.6

4.0

0,411

0,449

GPX1

198L

41.6

43.2

7.6

8.8

0,570

0,608